Glunomab: a novel therapeutics for the treatment of Parkinson’s Disease
Objective: The focus of this study was: 1) to characterize the expression and the localization of an endogenous protease, tissue plasminogen activator (tPA) in the…Results from IRL790C005 – A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study Evaluating the Efficacy of Mesdopetam on Daily On-Time without Troublesome Dyskinesia in Patients with Parkinson’s Disease
Objective: The objective of the Phase 2b-trial was to investigate efficacy and safety of three doses of Mesdopetam as adjunct treatment in patients with PD…Observations on 5 Parkinson’s patients taking Mucuna pruriens as natural source of levodopa
Objective: To explore potential benefits and tolerability of extracts from Mucuna pruriens for dopaminergic treatment of Parkinson’s patients. Background: Capsules containing freeze-dried, aqueous extract from…Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice
Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…Striatal Blood brain barrier opening in Parkinson´s disease
Objective: To test safety and feasibility of repeated low-intensity focused ultrasound (FUS) blood brain barrier opening (BBB) in the striatum of Parkinson’s disease (PD) patients.…Use of alternative healing for Parkinson’s disease in Kenya
Objective: To explore the experience of alternative healing practices by people with Parkinson’s disease in Kenya. Background: As a neurodegenerative condition, Parkinson’s disease (PD) requires…Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia
Objective: To evaluate the pharmacodynamic (PD) and safety profiles of subcutaneous (SC) administration of multiple ascending doses of CTI-1601 in patients age ≥18 years with…Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)
Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…Exosomes from human dental pulp stem cells as a cell-free drug delivery vehicle in vitro and in vivo chronic PD rat model through the intranasal route targeting efficacy & bio-distribution.
Objective: To evaluate the drug encasement in human dental pulp stem cell derived exosomes and its delivery in vitro in single cell level using fluorescence…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 11
- Next Page »